NASDAQ: STOK Stoke Therapeutics, Inc. 10-Q

Stoke advances Phase 3 Dravet trial toward mid-2027 data, posts $50M Q1 loss on lower revenue

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade STOK commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.